Jon Congleton insider trades

Open-market stock purchases and sales by Jon Congleton, Chief Executive Officer at Mineralys Therapeutics, Inc, from SEC Form 4 filings since Sep 11, 2015.

Track record: 100% of 4 scored buys are up 5% or more since purchase, averaging +120%.

Recent trades

DateStockTradeValue
Sep 30, 2026MLYS Mineralys Therapeutics, IncSold$1.9M
Jul 13, 2026MLYS Mineralys Therapeutics, IncSold$291K
Jul 5, 2026IMUX Immunic, IncBought (not open market)—
Jun 30, 2026MLYS Mineralys Therapeutics, IncSold$1.5M
Jun 30, 2026MLYS Mineralys Therapeutics, IncSold$456K
Jun 29, 2026IMUX Immunic, IncBought (not open market)—
Apr 29, 2026AVLN Avalyn Pharma IncBought (not open market)—
Apr 13, 2026MLYS Mineralys Therapeutics, IncSold$422K
Mar 31, 2026MLYS Mineralys Therapeutics, IncSold$494K
Mar 31, 2026MLYS Mineralys Therapeutics, IncSold$1.5M
Mar 31, 2026MLYS Mineralys Therapeutics, IncSold$12.3K
Feb 19, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Feb 19, 2026MLYS Mineralys Therapeutics, IncBought (not open market)—
Jan 12, 2026MLYS Mineralys Therapeutics, IncSold$236K
Jan 12, 2026MLYS Mineralys Therapeutics, IncSold$294K
Nov 21, 2025MLYS Mineralys Therapeutics, IncBought (not open market)—
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$533K
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$375K
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$174K
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$1.3M
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$5.1M
Nov 11, 2025MLYS Mineralys Therapeutics, IncSold$1.5M

Companies traded

  • MLYS Mineralys Therapeutics, Inc: 4 buys, 29 sales, last Sep 30, 2026
  • IMUX Immunic, Inc: other filings, last Jul 5, 2026
  • AVLN Avalyn Pharma Inc: other filings, last Apr 29, 2026
  • NVLS Nivalis Therapeutics, Inc: 4 buys, last Sep 12, 2016

Get free alerts when Jon Congleton files a new trade →